Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 28Carcinoma, Renal Cell 19Carcinoma, Non-Small-Cell Lung 13Carcinoma, Hepatocellular 10Brain Neoplasms 7Skin Neoplasms 6Neoplasm Metastasis 6Clear-cell metastatic renal cell carcinoma 6Neoplasms 5Kidney Neoplasms 5Colorectal Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Pancreatic Neoplasms 4Lung Neoplasms 4Carcinoma, Transitional Cell 4Triple Negative Breast Neoplasms 3Multiple Myeloma 3Mesothelioma 3Liver Neoplasms 3Breast Neoplasms 3Uveal Melanoma 2Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Sarcoma 2Recurrence 2Prostatic Neoplasms 2Mesothelioma, Malignant 2Lymphoma, Non-Hodgkin 2Glioblastoma 2Colonic Neoplasms 2

Interventions

Nivolumab 2Magnetic Resonance Spectroscopy 2trastuzumab deruxtecan 1tamibarotene 1cabozantinib 1Ultrasonography 1Specimen Handling 1Ipilimumab 1Cisplatin 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Urethral Neoplasms × Ipilimumab × Clear all
NCT03866382 2026-06-03

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

National Cancer Institute (NCI)

Phase 2 Recruiting
314 enrolled
Genitourinary

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡